US healthtech giant Boston Scientific’s pulmonary vein isolation (PVI) device trial has met its primary endpoint in patients ...

Boston Scientific Corporation BSX recently presented data supporting the use of the FARAPULSE Pulsed Field Ablation (“PFA”) ...

Boston Scientific (NYSE: BSX) today reported data from separate studies backing its Farapulse and Watchman FLX systems.

With Watchman, Boston Scientific estimates a 20% compound annual growth rate (CAGR) in 2025 with a high market share. Mahoney ...

also known as non-valvular AFib or NVAF. Washington Regional’s Walker Heart Institute now offers the Watchman FLX Pro Left ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.

The Watchman procedure helps those with atrial fibrillation (AFib ... procedure is an alternative for these people. The Watchman device is a small, parachute-shaped implant about the size ...

People with Afib have a five-times greater risk of stroke than those with normal heart rhythms, according to CHRISTUS. They state the WATCHMAN device is a small device implanted with a minimally ...

persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and efficacy outcomes with the WATCHMAN FLX ...

Boston Scientific (BSX) announced data supporting the use of the FARAPULSE Pulsed Field Ablation System* and the WATCHMAN ...